MONTREAL, Feb. 22, 2006 (PRIMEZONE) -- Viropro, Inc. (OTCBB:VPRO) -- an expert in the development and transfer of technologies for biogeneric recombinant products -- is proud to announce that it has retained the services of the public relations firm HKDP Communications and public affairs to build its image and name recognition on international financial and biopharmaceutical markets.
The immediate objective of the new management team at Viropro is to maximize the return on investment while at the same time responding to medical needs. With the recent appointment of Dr. Jean-Marie Dupuy as CEO, the Viropro team reinforced the company's foundation. It has developed an innovative business model based on technologies and quality products that both respond to medical needs and generate immediate financial benefits for company stock holders.
Also, Viropro intends to raise its profile through a combination of various communication projects, public relations and media relations. This is why Viropro is retaining the services of HKDP which will have the mandate to publicize new technology acquisitions agreements, business partnerships as well as new business contracts once finalized.
Viropro's CEO, Dr, Jean-Marie Dupuy, emphasizes that he has high hopes for this new association with HKDP. "We know that it is one of the most energetic and creative public relations firm in Canada. HKDP will be able to get our core message out about the rapid growth of Viropro based on the remarkable contributions of the team and I am confident that our association will be a real success story."
Jacques C. Gagnon, Director for Health and Pharmaceuticals at HKDP, stated "We are extremely proud of the trust Viropro is placing in our firm. It is exciting to be asked to provide services to a company experiencing rapid and sustained growth, both at the local and international levels, with products and a business model that clearly distinguishes them within their industry."
About Viropro, Inc.
Viropro, Inc. (OTCBB:VPRO) operates mainly through its subsidiary Viropro International Inc., with headquarters in Montreal, Canada. Viropro International continues to rapidly expand its portfolio of technologies and exclusive biogeneric recombinant products in the life sciences field, thanks to its strong strategic alliances with key partners and diverse business projects. These projects include technology transfers to pharmaceutical companies on the international market, thereby enabling the company to target short-term revenues while at the same time increasing the value of its shares and those of its shareholders.
For more information on Viropro Inc., please visit our website on www.viropro.com
About HKDP Communications and public affairs
One of Quebec leading communication and public affairs firm, HKDP Communications and public affairs, is a fully owned subsidiary of Hill & Knowlton with 73 offices in 39 countries. HKDP employs thirty professionals in its Quebec and Montreal offices.
About Hill & Knowlton Canada
Hill & Knowlton Canada (www.hillandknowlton.ca) is Canada's leading public affairs and public relations firm specializing in government relations and corporate, crisis, consumer marketing, technology, healthcare and life sciences communications as well as financial and investor relations. Hill & Knowlton Canada is also a recipient of Level 2 Certification under the National Quality Institute's Progressive Excellence Program. Its parent company, Hill & Knowlton, Inc, is a world leader in public relations and public affairs, with 73 offices in 39 countries, and is part of the WPP Group plc (Nasdaq:WPPGY) (www.wpp.com), one of the world's largest communications services groups.
Viropro, Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbour created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.